GOSS Gossamer Bio Inc
Price (delayed)
$0.88
Market cap
$199.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.33
Enterprise value
$309.25M
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an
Highlights
The quick ratio has soared by 96% year-on-year and by 16% since the previous quarter
GOSS's EPS has soared by 85% year-on-year and by 67% since the previous quarter
Key stats
What are the main financial stats of GOSS
Market
Valuations
Earnings
Shares outstanding
226.23M
Market cap
$199.08M
Enterprise value
$309.25M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.44
Price to sales (P/S)
2.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.23
Revenue
$95.84M
EBIT
-$63.79M
EBITDA
-$59.72M
Free cash flow
-$3.87M
Per share
Balance sheet
Liquidity
EPS
-$0.33
Free cash flow per share
-$0.02
Book value per share
$0.36
Revenue per share
$0.42
TBVPS
$1.65
Total assets
$373.45M
Total liabilities
$291.92M
Debt
$197.05M
Equity
$81.53M
Working capital
$325.72M
Debt to equity
2.42
Current ratio
8.21
Quick ratio
7.93
Net debt/EBITDA
-1.84
Margins
Efficiency
Dividend
EBITDA margin
-62.3%
Gross margin
100%
Net margin
-84.4%
Operating margin
-82.8%
Return on assets
-25%
Return on equity
-117.3%
Return on invested capital
-15%
Return on capital employed
-19.4%
Return on sales
-66.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GOSS stock price
How has the Gossamer Bio stock price performed over time
Intraday
-1.13%
1 week
-8.4%
1 month
10.69%
1 year
-7.29%
YTD
-3.56%
QTD
-2.32%
Financial performance
How have Gossamer Bio's revenue and profit performed over time
Revenue
$95.84M
Gross profit
$95.84M
Operating income
-$79.39M
Net income
-$80.85M
Gross margin
100%
Net margin
-84.4%
Gossamer Bio's operating income has surged by 61% YoY and by 55% QoQ
Gossamer Bio's net income has soared by 61% YoY and by 53% from the previous quarter
Growth
What is Gossamer Bio's growth rate over time
Valuation
What is Gossamer Bio stock price valuation
P/E
N/A
P/B
2.44
P/S
2.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.23
GOSS's EPS has soared by 85% year-on-year and by 67% since the previous quarter
The P/B is 61% less than the 5-year quarterly average of 6.4 and 44% less than the last 4 quarters average of 4.4
Efficiency
How efficient is Gossamer Bio business performance
The company's return on equity has surged by 78% QoQ
Gossamer Bio's ROIC has soared by 74% YoY and by 63% from the previous quarter
GOSS's ROA has soared by 70% year-on-year and by 60% since the previous quarter
Dividends
What is GOSS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GOSS.
Financial health
How did Gossamer Bio financials performed over time
GOSS's total assets is 28% higher than its total liabilities
GOSS's total assets has soared by 105% YoY and by 44% QoQ
The quick ratio has soared by 96% year-on-year and by 16% since the previous quarter
The debt is 142% greater than the equity
The company's debt to equity has surged by 170% YoY but it has shrunk by 69% QoQ
The debt has declined by 9% year-on-year and by 4.5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.